Skip to main content

Advertisement

SpringerLink
Log in

Gastrointestinal cancer

Adjuvant chemotherapy after D2 gastrectomy for gastric cancer

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

This article has been updated

In the CLASSIC study, capecitabine–oxaliplatin was an effective chemotherapy after D2 gastrectomy for stage II–IIIB gastric cancer. We compared these data with the ACTS-GC study, which was the only pivotal study proving the benefit of adjuvant chemotherapy in these patients. Long-term survival data from CLASSIC are awaited with interest.boxed-text

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 15 March 2012

    In the version of this article initially published online the data for survival in the ACTS-GC trial were incorrect in Table 1. The 3-year RFS should be 72.2% vs 59.6% and the 3-year OS should be 80.1% vs 70.1%. The error has been corrected for the print, HTML and PDF versions of the article.

References

  1. Macdonald, J. S. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345, 725–730 (2001).

    Article  CAS  Google Scholar 

  2. Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11–20 (2006).

    Article  CAS  Google Scholar 

  3. Sasako, M. et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 29, 4387–4393 (2011).

    Article  CAS  Google Scholar 

  4. Hundahl, S. A. et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann. Surg. Oncol. 9, 278–86 (2002).

    Article  Google Scholar 

  5. Wu, C. W. et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 7, 309–315 (2006).

    Article  CAS  Google Scholar 

  6. Okines, A. et al. Gastric Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl. 5), v50–v54 (2010).

    Article  Google Scholar 

  7. NCCN. NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer Version 2.2011 [online], (2011).

  8. Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379, 315–321 (2012).

    Article  CAS  Google Scholar 

  9. Macdonald, J. S. Gastric cancer: Nagoya is not New York. J. Clin. Oncol. 29, 4348–4350 (2011).

    Article  Google Scholar 

  10. Lee, J. Y. et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J. Clin. Oncol. 30, 268–273 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-Ku, 241-0815, Yokohama, Japan

    Takaki Yoshikawa

  2. Department of Upper Gastrointestinal Surgery, Hyogo College of Medicine, 1-1 Mukogawa-Cho, Nishinomiya, 663-8501, Hyogo, Japan

    Mitsuru Sasako

Authors
  1. Takaki Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitsuru Sasako
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitsuru Sasako.

Ethics declarations

Competing interests

M. Sasako is a consultant for and receives honoraria and grant support from Chugai Pharmaceuticals and Taiho Pharmaceuticals. M. Sasako also receives honoraria and grant support from Sanofi-Aventis. T. Yoshikawa declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshikawa, T., Sasako, M. Adjuvant chemotherapy after D2 gastrectomy for gastric cancer. Nat Rev Clin Oncol 9, 192–194 (2012). https://doi.org/10.1038/nrclinonc.2012.23

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2012.23

  • Springer Nature Limited

This article is cited by

Search

Navigation